

UroPACA 2026 Program

Deciding today. Building tomorrow. The congress where experts explain their decisions.

Thursday, December 3, 2026

Dec 3 • 08:50 - 09:00

Welcome Address & Institutional Session:

Welcome

08:50 - 09:00

Introduction & opening address by the Secretary General of the AFU

- Prof. J BRANCHEREAU, Dr O ALENDIA

Dec 3 • 09:00 - 09:30

THE UROPACA TRIALS: The Trial of Systematization

UroPACA Trials

Moderators: Prof. M SOULIE, Dr A FLECHON, Prof. R MATHIEU, Prof. JM HANNOUN

09:00 - 09:30

Charge: PROSTATE (The Blind Triplet)

“The accused will rise: You initiated triplet therapy (castration + docetaxel + ARPI) in a de novo mHSPC patient without assessing his cardiovascular health or cognition (ARACOG data).”

- Dr C HELISSEY

09:00 - 09:30

Charge: PROSTATE (The Rigid Surveillance)

“The accused will rise: You continue to offer rigid active surveillance for an ISUP 2 patient without genomic profiling or molecular scores.”

- Dr M BABOUDJAN

Dec 3 • 09:30 - 10:00

SPECIAL SESSION: THE MDT SURVIVAL GUIDE

Special session

Moderators: Prof. M SOULIE, Dr A FLECHON, Prof. R MATHIEU, Prof. JM HANNOUN

09:30 - 10:00

“What can we actually prescribe or offer on Monday morning?” — Active marketing authorizations & reimbursements in France

Review of the molecules immediately accessible, by disease stage.

- Dr B AUBERGER

09:30 - 10:00

“What can we actually prescribe or offer on Monday morning?” — Early Access (AAC / CPC)

Which molecules are available through exceptional access today (e.g. HIF inhibitors, next-generation ADCs, neoadjuvant combinations) and for exactly which patient profiles?

- Prof. Y NEUZILLET

09:30 - 10:00

“What can we actually prescribe or offer on Monday morning?” — Referral to Clinical Trials

Which therapeutic windows remain open for enrolling our patients from MDT meetings (active national/regional trials) in case of a therapeutic dead end, or to avoid a loss of chance?

- “MDT memo”-type summary sheet downloadable via QR code in the room.

- Dr M VELEV

Dec 3 • 10:00 - 10:30

BREAK AND VISIT TO THE EXHIBITION STANDS

Break

Dec 3 • 10:30 - 10:50

CURIUM SYMPOSIUM

Symposium

Moderator: **Prof. S CROUZET**

10:30 - 10:50

“Impact of PSMA PET in the initial staging of prostate cancer.”

- Objectives: When to use PSMA versus conventional imaging (bone scan/CT) and what direct impact for the urologist/radiotherapist.

● Dr C MERLIN

Dec 3 • 10:50 - 11:10

MSD SYMPOSIUM

Symposium

10:50 - 11:10

“Hypoxia and kidney cancer: new therapeutic opportunities with HIF inhibitors.”

● Prof. P BIGOT, Dr D BORCHIELLINI

Dec 3 • 11:10 - 11:50

ASTELLAS SYMPOSIUM

Symposium

11:10 - 11:50

Personalizing management in uro-oncology at the heart of therapeutic decisions: mHSPC and metastatic urothelial carcinoma, what strategy in 2026?

● Dr M SOUQUET BRESSAND

Dec 3 • 11:50 - 12:30

BAYER SYMPOSIUM

Symposium

Moderator: **Prof. R MATHIEU**

11:50 - 12:30

Prostate cancer mHSPC — State of the art in the management of mHSPC

● Prof. Y NEUZILLET

11:50 - 12:30

Prostate cancer mHSPC — How to personalize treatment at the mHSPC stage?

● Dr N BENZIANE

Dec 3 • 12:30 - 14:00

PROTECTED LUNCH BREAK AND VISIT TO THE EXHIBITION STANDS

Break

Dec 3 • 14:00 - 14:30

RED CARD:

Red Card

Moderators: **Dr C HELLISEY, Prof. C HENNEQUIN, Prof. JL DESCOTES**

14:00 - 14:30

Prostate: “Detectable PSA after prostatectomy: should we treat the PSA or the patient? Early, with which weapons, before turning a biochemical alert into therapeutic escalation? And how long should we wait?”

● Dr A MACAGNO

14:00 - 14:30

Germ cell tumor: “Red card for never-ending chemotherapy: when should we know to hand over to the surgeon?”

● Prof. X DURAND

Dec 3 • 14:30 - 15:10

CHANGES TO YOUR PRACTICE BASED ON THE NEW GUIDELINES (CCAFU)

Practice changes (CCAFU)

Moderators: Dr C HELLISEY, Prof. C HENNEQUIN, Prof. JL DESCOTES

14:30 - 15:10

KIDNEY PATHWAY

● Prof. P BIGOT

14:30 - 15:10

BLADDER PATHWAY

● Prof. Y NEUZILLET

14:30 - 15:10

PROSTATE PATHWAY

● Prof. R MATHIEU

14:30 - 15:10

EXTERNAL GENITALIA (OGE) AND ADRENAL PATHWAY

● Prof. P SAVOIE

Dec 3 • 15:10 - 15:30

KIDNEY: WHEN GUIDELINES ARE NO LONGER ENOUGH?

Kidney

Moderators: Dr C HELLISEY, Prof. C HENNEQUIN, Prof. JL DESCOTES

15:10 - 15:30

Oligometastatic recurrence of kidney cancer: aim for NED (no evidence of disease) first and then treat, or intensify from the outset?

● Dr R FLIPPOT

Dec 3 • 15:50 - 16:10

MENTORING & SIMULATION SESSION (AFUF partnership)

Mentoring & Simulation session

Moderators: Dr C HELLISEY, Prof. C HENNEQUIN, Prof. JL DESCOTES

15:50 - 16:10

“The decline of open surgery and laparoscopy in the face of all-robotic: how to train the younger generation to manage a major complication without a console?”

• Debate: Sustaining emergency conversion skills in surgery

● Prof. J BRANCHEREAU, Prof. S CROUZET

Dec 3 • 16:10 - 16:30

BREAK AND VISIT TO THE EXHIBITION STANDS

Break

Dec 3 • 16:30 - 16:50

BMS SYMPOSIUM

Symposium

16:30 - 16:50

Does the subcutaneous route of immunotherapy facilitate the patient pathway and the oncology unit's organization?

● Prof. S OUDARD, RN

Dec 3 • 16:50 - 17:10

PFIZER SYMPOSIUM

Symposium

16:50 - 17:10

PARP inhibitors in prostate cancer: updates and perspectives

- PARP inhibitors in mHSPC: what evidence today?
- PARP inhibitors in mCRPC: what place in current strategies?

● Dr A FLECHON, Dr T CHEVALIER

Dec 3 • 17:10 - 17:40

INNOVATION SESSION: AI, THE MICROBIOTA & THE INTRAOPERATIVE SETTING

Innovation session

Moderators: **Prof. A MEJEAN, Prof. S CROUZET**

17:10 - 17:40

AI in your daily practice

“Does my predictive segmentation algorithm replace my expert eye for planning the resection?”

● Prof. M DURAND

17:10 - 17:40

Microbiota

“Gut flora analysis: the ultimate biomarker before starting immunotherapy?”

● Dr P GARCIA

17:10 - 17:40

Innovation

“Intraoperative use of the confocal scanner: gadget or revolution for surgical margins?”

● Dr W ABOU CHEDID

Dec 3 • 17:40 - 18:00

THE UROPACA CULTURAL INTERLUDE

Cultural Interlude

17:40 - 18:00

“Illness and the allegorical representation of health in Nabi painting at the end of the 19th century.”

The idea: 20 minutes of artistic breathing space away from the operating room to analyze how pre-modern art (Bonnard, Vuillard, Maurice Denis) captured the vulnerability of the body and the concept of healing.

● Prof. MO BITKER

Friday, December 4, 2026

Dec 4 • 08:50 - 09:00

Welcome Address & Institutional Session:

Welcome

08:50 - 09:00

Introduction & opening address by the President of the AFU

- Dr A FAIX, Dr O ALEND

Dec 4 • 09:00 - 10:30

SHOWDOWN SESSION: THE FUTURE OF CYSTECTOMY: Bladder tumors: from systematic resection to tailored surgery

Showdown session

Moderators: **Prof. T LEBRET, Dr N HOUÉDE, Dr JF BERDAH**

09:00 - 09:20

Act 1: NMIBC — From intravesical therapy to bladder-sparing surgery:

The challenge: Management of high-risk disease (T1, CIS, high-grade Ta) and BCG failures.

- For the advances: sustained-release devices (TAR-200), gene therapies and local/systemic immunotherapies.
- Dr G PIGNOT

09:00 - 09:20

Act 1: NMIBC — From intravesical therapy to bladder-sparing surgery:

● For early cystectomy (very high risk / non-responders), weighed against the risk of mutilating overtreatment vs. understaging.

- Dr A PANSADORO

09:20 - 09:50

Act 2: MIBC — The clash between surgery and organ preservation

● The systemic breakthrough: complete pathological response rates (pT0 > 50-60%) with ADC + anti-PD1 combinations (EV-Pembro).

- Dr B AUBERGER

09:20 - 09:50

Act 2: MIBC — The clash between surgery and organ preservation

● Biomarkers & imaging: Is cystectomy necessary in complete responders (negative ctDNA, VI-RADS 1)?

- Prof. F AUDENET

09:20 - 09:50

Act 2: MIBC — The clash between surgery and organ preservation

● Modern trimodality therapy: role of TURBT + radiotherapy (SBRT/IGRT) + radiosensitization regimens to match overall survival with bladder preservation.

- Dr E GROSS

09:50 - 10:20

Act 3: Robotic surgery — Redefining modern cystectomy:

● Robotic cystectomy and intracorporeal reconstruction: how far to go to preserve quality of life?

- Dr L LOPEZ

09:50 - 10:20

Act 3: Robotic surgery — Redefining modern cystectomy:

● Salvage cystectomy after conservative treatment: when surgery becomes a real headache!

- Prof. F ANNINO

10:20 - 10:30

Summary & Monday-morning MDT algorithm:

● Paradigm shift: from the systematic trip to the operating room toward armed surveillance (Watch & Wait) guided by biomarkers.

● Interactive audience vote: how the audience's convictions evolve on the place of upfront cystectomy.

- Dr G PIGNOT

Dec 4 • 10:30 - 11:00

BREAK AND VISIT TO THE EXHIBITION STANDS

Break

Dec 4 • 11:00 - 11:20

IPSEN SYMPOSIUM

Symposium

11:00 - 11:20

"mRCC in real life: from MDT to decision, how to personalize first-line therapy?"

- Metastatic patient: what place for cytoreductive nephrectomy? – 10 min.
- Patient under-represented in phase III trials: beyond the standard patient - 10 min.

● Prof. MO TIMSIT, Dr C HELISSEY

Dec 4 • 11:20 - 11:40

BREAKING NEWS: FIRST LOOK AT THE RESULTS: THE EMUPRO STUDY

Breaking news

11:20 - 11:40

The big verdict on the benefits of robot-assisted surgery

● Prof. T PIECHAUD

Dec 4 • 11:40 - 12:20

JOHNSON & JOHNSON SYMPOSIUM

Symposium

11:40 - 12:20

From disease control to quality of life: 3 key questions in prostate cancer

● Prof. MO TIMSIT, Dr N USDIN, Dr A TOLEDANO

Dec 4 • 12:20 - 13:30

LUNCH BREAK AND VISIT TO THE EXHIBITION STANDS

Break

Dec 4 • 13:30 - 14:10

ASTRAZENECA SYMPOSIUM

Symposium

13:30 - 14:10

Management of bladder cancer, from non-muscle-invasive (NMIBC) to muscle-invasive (MIBC) forms: current optimization and therapeutic perspectives.

- Cross-disciplinary approach: Dr D BORCHIELLINI (Oncologist) & Prof. R BOISSIER (Urologist).

● Dr D BORCHIELLINI, Prof. R BOISSIER

Dec 4 • 14:10 - 15:10

SPECIAL SESSION: DE-ESCALATION AND SURGICAL RESERVE: When Oncology and Radiotherapy push back the scalpel

Special session

Moderators: Prof. A MEJEAN, Prof. S OUDARD, Prof. C HENNEQUIN, Prof. C BASTIDE

14:10 - 15:10

Case 1 (Kidney): “Complete response on immunotherapy doublet: why on earth would I remove the kidney?”

- The oncologist: Continuing systemic treatment alone

● Dr Y VANO

14:10 - 15:10

Case 1 (Kidney): “Complete response on immunotherapy doublet: why on earth would I remove the kidney?”

- The urologist: Deferred cytoreductive nephrectomy

● Prof. K BENSALAH

14:10 - 15:10

Case 1 (Kidney): “Complete response on immunotherapy doublet: why on earth would I remove the kidney?”

- The radiotherapist: Closing SBRT of the residual disease.

● Prof. O CHAPET

14:10 - 15:10

Case no. 2 - Very-high-risk prostate cancer: why on earth do you still want to operate?

- The radiotherapist: “I can treat the prostate and the pelvis and intensify systemic treatment: what does your prostatectomy really add?”

● Dr M TERLIZZI

14:10 - 15:10

Case no. 2 - Very-high-risk prostate cancer: why on earth do you still want to operate?

- The oncologist: “If I already consider this disease as potentially systemic, why start with the scalpel?”

● Dr A FLECHON

14:10 - 15:10

Case no. 2 - Very-high-risk prostate cancer: why on earth do you still want to operate?

- The urologist: “In our drive to treat an invisible disease, aren't we abandoning surgical control of the visible disease too quickly?”

● Prof. M ODERDA

Dec 4 • 15:10 - 15:30

BREAK AND VISIT TO THE EXHIBITION STANDS

Break

Dec 4 • 15:30 - 16:10

NOVARTIS SYMPOSIUM

Symposium

15:30 - 16:10

“Radioligand therapy (RIV): driving the evolution of mCRPC management today, and of mHSPC tomorrow?”

● Dr O CASSUTO, Dr E BOUILLLOUX

Dec 4 • 16:10 - 16:40

ACT: SURGICAL NIGHTMARES IN ROBOTICS

Act

Moderators: Prof. T PIECHAUD, Prof. J BRANCHERAU

16:10 - 16:40

“When the robot turns into a nightmare: how to get out of operative hell?”

The case: Ureteral avulsion, major vascular injury or unexpected complication during a complex robotic partial nephrectomy.

- Raw video: A real complication, unfiltered and without reassuring editing.
- Freeze frame: The incident occurs. What decision to make?
- The experts' challenge: How to regain control, repair and avoid catastrophe?
- The verdict: Analysis of errors, rescue strategies and medico-legal lessons.

● Dr Y. AHALLAL, Prof. T PIECHAUD

Dec 4 • 16:40 - 17:30

CLOSING: TABOOS: “Do as I say, not as I do”

Closing: Taboos

16:40 - 17:30

“Do as I say, not as I do” — “Why I never monitor the urethra after total cystectomy, despite the AFU guidelines?”

Confessional session, no holds barred, with continuous live audience voting.

● Dr PO FAIS

16:40 - 17:30

“Do as I say, not as I do” — “Why I do NOT systematically perform a renal biopsy before nephrectomy”

Confessional session, no holds barred, with continuous live audience voting.

● Prof. A MEJEAN

16:40 - 17:30

“Do as I say, not as I do” — “Which 2026 novelty have I already integrated into my presentations, but not yet into my practice”

Confessional session, no holds barred, with continuous live audience voting.

● Prof. R BOISSIER

16:40 - 17:30

“Do as I say, not as I do” — “Why I don't perform the second TURBT (second look) on a T1G3 even though it is the standard?”

Confessional session, no holds barred, with continuous live audience voting.

● Prof. T LEBRET

With the support of:

Astellas • AstraZeneca • Bayer • Bristol Myers Squibb • Curium • IPSEN • Johnson & Johnson • MSD • Novartis • Pfizer • Laboratoire Thérascience • Accord • Arard • Boston Scientific • Coloplast • Hollister • IBSA • La Médicale • MicroPort • Pierre Fabre • Recordati • Viatris • Diadom • Intuitive Surgical • Elsan